These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 30575989)

  • 1. Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.
    Pastori D; Mezzaroma I; Pignatelli P; Violi F; Lip GYH
    Br J Clin Pharmacol; 2019 Mar; 85(3):508-515. PubMed ID: 30575989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of atrial fibrillation after atrial flutter ablation: impact of AF history, gender, and antiarrhythmic drug medication.
    Brembilla-Perrot B; Girerd N; Sellal JM; Olivier A; Manenti V; Villemin T; Beurrier D; DE Chillou C; Louis P; Selton O; DE LA Chaise AT
    J Cardiovasc Electrophysiol; 2014 Aug; 25(8):813-820. PubMed ID: 24654647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Comparison of Classes IC and III Antiarrhythmic Drugs as an Initial Rhythm Control Strategy in Newly Diagnosed Atrial Fibrillation: From the TREAT-AF Study.
    Kipp R; Askari M; Fan J; Field ME; Turakhia MP
    JACC Clin Electrophysiol; 2019 Feb; 5(2):231-241. PubMed ID: 30784696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: management of recent-onset atrial fibrillation and flutter in the emergency department.
    Stiell IG; Macle L;
    Can J Cardiol; 2011; 27(1):38-46. PubMed ID: 21329861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
    Stambler BS; Wood MA; Ellenbogen KA
    Circulation; 1997 Dec; 96(12):4298-306. PubMed ID: 9416896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibutilide: an antiarrhythmic agent for the treatment of atrial fibrillation or flutter.
    Howard PA
    Ann Pharmacother; 1999 Jan; 33(1):38-47. PubMed ID: 9972384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial arrhythmia prevalence and characteristics for human immunodeficiency virus-infected persons and matched uninfected controls.
    Sanders JM; Steverson AB; Pawlowski AE; Schneider D; Achenbach CJ; Lloyd-Jones DM; Feinstein MJ
    PLoS One; 2018; 13(3):e0194754. PubMed ID: 29558525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The differentiated therapy of paroxysms of atrial fibrillation and flutter in patients with ischemic heart disease in relation to the duration of the arrhythmia before the start of treatment].
    Shabrov AV; Olesin AI; Golub IaV; Smolin ZIu
    Ter Arkh; 1998; 70(8):25-9. PubMed ID: 9770739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and atrial flutter: medical management.
    Chen J
    Clin Geriatr Med; 2012 Nov; 28(4):635-47. PubMed ID: 23101574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of isolated atrial flutter versus atrial flutter combined with atrial fibrillation.
    Peyrol M; Sbragia P; Bonello L; Lévy S; Paganelli F
    Arch Cardiovasc Dis; 2011 Oct; 104(10):530-5. PubMed ID: 22044706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
    Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Oliveira MM; Mairesse G; Crijns HJ; Simantirakis E; Atar D; Kirchhof P; Vardas P; Tavazzi L; Maggioni AP
    Europace; 2014 Mar; 16(3):308-19. PubMed ID: 24351881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices.
    Banerjee A; Marín F; Lip GY
    Stroke; 2011 Nov; 42(11):3316-22. PubMed ID: 21998051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrial fibrillation and atrial flutter.
    Geraets DR; Kienzle MG
    Clin Pharm; 1993 Oct; 12(10):721-35; quiz 783-4. PubMed ID: 7903069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation of Cardiovascular Conditions in the Cancer Patient: Review of Old and New Therapies.
    Rhea IB; Lyon AR; Fradley MG
    Curr Oncol Rep; 2019 Apr; 21(5):45. PubMed ID: 30949848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA; Kuhn RJ; McCaffrey FM
    Ann Pharmacother; 1997 Nov; 31(11):1347-59. PubMed ID: 9391691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary vein triggers play an important role in the initiation of atrial flutter: Initial results from the prospective randomized Atrial Fibrillation Ablation in Atrial Flutter (Triple A) trial.
    Schneider R; Lauschke J; Tischer T; Schneider C; Voss W; Moehlenkamp F; Glass A; Diedrich D; Bänsch D
    Heart Rhythm; 2015 May; 12(5):865-71. PubMed ID: 25638698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation and atrial flutter in athletes.
    Calvo N; Brugada J; Sitges M; Mont L
    Br J Sports Med; 2012 Nov; 46 Suppl 1():i37-43. PubMed ID: 23097477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model.
    Rossman EI; Liu K; Morgan GA; Swillo RE; Krueger JA; Gardell SJ; Butera J; Gruver M; Kantrowitz J; Feldman HS; Petersen JS; Haugan K; Hennan JK
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1127-33. PubMed ID: 19252062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Termination of Atrial Flutter and Fibrillation by K201's Metabolite M-II: Studies in the Canine Sterile Pericarditis Model.
    Sadrpour SA; Serhal M; Khrestian CM; Lee S; Fields T; Dittrich HC; Waldo AL
    J Cardiovasc Pharmacol; 2015 May; 65(5):494-9. PubMed ID: 25636078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.